Podcasts about transplantation

Michael Bretthauer and Thomas LaMont discuss a new randomized study on the use of fecal transplantation versus vancomycin in primary clostridium difficile infection

An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Societyfor Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University Health Stephenson Cancer Center and serves as an ambassador for ASCO. The group highlighted several late-breaking abstracts, plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following: ·       Phase 1b/2 CARTITUDE-1 trial (NCT03548207, NCT05201781) o   Long-term follow-up showed that approximately one-third (33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti).  o   An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas. o   With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-not evaluable [NE]). ·       Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use o   Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma. o   Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. o   Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings. ·       Phase 1b/2 NEXICART-2 trial (NCT06097832) o   Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options. o   Among 12 patients who received the agent at 450 x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively.  o   With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred. References 1. Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.7507 2. Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.7023 3. Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508. doi:10.1200/JCO.2025.43.16_suppl.7508

Host Roz is joined by new co-host Alberto Sanchez-Fueyo, MD, PhD to discuss the key articles of the June issue of the American Journal of Transplantation. Dr. Sanchez-Fueyo is a Professor of Hepatology, and the Academic Director of the Institute of Liver Studies, King's College, London. [02:51] Recipient toll-like receptor 4 determines the outcome of ischemia-reperfusion injury in steatotic liver transplantation in mice [10:47] Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study [21:35] Balancing equity and human leukocyte antigen matching in deceased-donor kidney allocation with eplet mismatch Editorial: Equitable allocation through human leukocyte antigen eplet matching: A promising strategy with several challenges [32:51] Impact of the lung allocation system score modification by blood type on US lung transplant candidates Editorial: From flawed to fairer: Reducing blood type bias in lung transplant allocation Recommended article: The economic value of a transplant nephrologist: The case for improving compensation models

Katie Payne is the Chief Executive Officer of Lifebanc, Northeast Ohio's only nonprofit organ and tissue recovery organization. A registered nurse and healthcare leader with nearly two decades of experience in transplant and donation services, Katie brings deep clinical expertise and a personal passion for saving lives through donation.Her journey into this work is rooted in personal loss—her brother Billy became a donor after a tragic accident, an experience that profoundly shaped her sense of vocation. Prior to joining Lifebanc, Katie served as Executive Director at LifeLink of Georgia, where she led operations across clinical services, hospital development, donor family support, and public education, helping increase donation volumes by 18% and organs transplanted by 36%. Katie holds a Master of Science in Nursing from the University of Tennessee Health Science Center and a Bachelor of Arts in Journalism from Georgia State University. She is a member of the American College of Healthcare Executives and the Association for Multicultural Affairs in Transplantation. With a leadership style grounded in empathy, data, and advocacy, Katie is committed to honoring every donor, supporting families, and bridging the gap between need and access in organ and tissue donation.

In this specialty podcast, Dr. Alissar El Chediak is joined by Dr. Jon Odorico and Dr. Ron Parsons to discuss the current state of pancreas transplantation, identify barriers and strategies for referral and candidate selection, and discuss solutions to address the decline in procedures. Alissar El Chediak, MD is a transplant nephrologist at UT Southwestern Medical Center. Jon Odorico, MD is a transplant surgeon at the University of Wisconsin. Ron Parsons, MD is a transplant surgeon at the University of Pennsylvania.   References: Generating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report

3ème épisode / 5, de la série vascularites à ANCA Episode 3 : Le point de vue du Néphrologue. Invité : Pr Alexandre Hertig, néphrologue, chef du service de néphrologie de l'hôpital Foch à Suresnes et membre du conseil d'administration de la SFNDT, la Société Francophone de Néphrologie Dialyse et Transplantation. https://www.hopital-foch.com/offre-de-soins/nephrologie/     https://www.sfndt.org/    1️⃣   Qui sont les patients concernés par une atteinte rénale lors d'une vascularite à ANCA ? [0'27 – 0'46] ✔️La plupart des patients sont âgés de plus de 50 ans. Pour plus d'informations, retrouvez notre page article : https://rarealecoute.com/la-vascularite-a-anca/ 2️⃣   Comment se manifeste l'atteinte rénale et quand la soupçonner ? [0'47 – 1'44] ✔️ Hématurie avec protéinurie glomérulaire, ✔️ Glomérulonéphrite rapidement progressive. 3️⃣   Comment affirmer le diagnostic ? [1'45 -2'28] ✔️ Biopsie rénale montrant une glomérulonéphrite extra-capillaire pauci-immune. 4️⃣   Quel est le pronostic rénal des patients diagnostiqués ? [2'29 – 3'31] ✔️ Il dépend du nombre de poussées antérieures et de l'étendue des lésions rénales. 5️⃣   Quelle prise en charge rénale proposer ? [3'32 – 5'26] ✔️ Corticoïdes à forte dose, immunosuppresseurs... ✔️ Médicaments néphroprotecteurs. 6️⃣   Comment s'opère la coordination des soins les patients concernés ? [5'27 – 6'18] ✔️ Coopération néphrologues - médecins internistes.   L'équipe : Virginie Druenne – Ambassadrice RARE à l'écoute Cyril Cassard – Journaliste/Animation Hervé Guillot - Production Crédits : Sonacom ***************************************************************************************************************** À propos : "RARE à l'écoute" est un podcast dédié à la sensibilisation aux maladies rares et au soutien des personnes touchées par ces affections. Créé par un groupe passionné de professionnels de la santé, le podcast vise à informer les professionnels de santé et fournissant des informations sur les dernières avancées médicales et scientifiques dans le domaine des maladies rares, et inspirer les patients et leurs proches en partageant des histoires de courage et de persévérance. Contenu :

durée : 00:03:29 - Opération spectaculaire de transplantation des palmiers de la place Clemenceau à Pau

In dieser Folge sprechen wir über die kürzlich veröffentlichte multizentrische, randomisierte Phase-III-Studie zur hypothermen oxygenierten Maschinenperfusion (HOPE) bei Lebertransplantationen. Die Studie untersuchte, ob HOPE nach klassischer Kaltlagerung die Komplikationsrate im ersten Jahr nach Transplantation senken kann. Zwar zeigte sich kein signifikanter Unterschied bei der Gesamtkomplikationsrate, doch spannende Ergebnisse aus einer Post-hoc-Analyse deuten darauf hin, dass HOPE das Risiko für schwere leberbezogene Komplikationen und das Leberversagen deutlich reduzieren könnte. Wir diskutieren, wie diese Methode im klinischen Alltag eingesetzt werden kann, was sie von anderen Perfusionstechnologien unterscheidet – und warum es sich lohnt, weitere Studien dazu durchzuführen.Moderation: Frau Dr. Frederike StelterGast: Prof. Dr. Roland CronerSchlegel A, Mueller M, Muller X, Eden J, Panconesi R, von Felten S, Steigmiller K, Sousa Da Silva RX, de Rougemont O, Mabrut JY, Lesurtel M, Cerisuelo MC, Heaton ND, Allard MA, Adam R, Monbaliu D, Jochmans I, Haring MPD, Porte RJ, Parente A, Muiesan P, Kron P, Attia M, Kollmann D, Berlakovich G, Rogiers X, Petterson K, Kranich AL, Amberg S, Müllhaupt B, Clavien PA, Dutkowski P. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J Hepatol. 2023 Apr;78(4):783-793. doi: 10.1016/j.jhep.2022.12.030. Epub 2023 Jan 19. PMID: 36681160.

Should animals ever be used as spare parts for humans? PETA Sr. VP Kathy Guillermo was interviewed by CNN about xenotransplantation.  Listen to what she had to say about the experience and the hope that her views are represented fairly.  See PETA represent the ethical perspective on xenotransplantation in the CNN documentary "Animal Pharm," which premieres Sunday, May 17. Find out more about xenotransplantation, go to PETA.org The PETA Podcast PETA, the world's largest animal rights organization, is 9 million strong and growing. Hosted by Emil Guillermo.  Contact us at PETA.org Music provided by CarbonWorks. Go to Apple podcasts and subscribe. Contact and follow host Emil Guillermo and get the podcast on YouTube. www.YouTube.com/@emilamok1 Please subscribe, rate, and review wherever you get your podcasts. Thanks for listening to THE PETA PODCAST! Originally released May 14, 2025,  ©PETA, Emil Guillermo 2023-25  

How do you lead as a woman of colour in surgery? Join us as Hannah Maple sits down with Evelyn Mensah and Sala Abdalla to discuss the experiences of women of colour in surgery from personal stories, the impact of racism, and theirjourneys towards leadership. We delve into the importance of leadership, offering advice for aspiring women surgeons, and emphasise the power of visibility and support. Don't miss this compelling conversation that challenges and inspires!Guest: Evelyn MensahEvelyn (Evie) Mensah, Consultant Ophthalmologist and WRES Expert at London North West University Healthcare NHS Trust is part of the London and Medical WRES Strategy Groups. Evie leads ophthalmology and anti-racism initiatives globally, aiming for equitable healthcare. She championsinstitutional courage. In October 2024, Evie was appointed as the President for the Ophthalmology section of the Royal Society of Medicine. During her two year tenure she hopes to foster closer relationships between ophthalmologists andthe wider multi-disciplinary team.Guest: Sala AbdallaDr Sala Abdalla is a Consultant General, Emergency and Upper Gastrointestinal (GI) Surgeon at the London North West University Healthcare Trust. Dr Abdalla is the author of numerous publications in the field of surgery and surgical education including two textbooks; 'A History of Surgery' which she co-authored with Harold Ellis CBE FRCS, showcasing her dedication to exploring the rich history of surgical practices across the globe, and 'Cracking the general surgical interviews for ST3', which serves as a valuable preparatory resource for aspiring surgeons. DrAbdalla is deeply invested in advancing global access to surgical care. She is the founder and director of a surgical charity called Operation International UK which has close collaboration with the Royal College of Surgeons of England. Her charity delivers free surgical care and education tounderserved communities around the world. She has received two national awards for her charitable work and cites her charity as one of her proudest achievements. Hosted by: Hannah MapleHannah Maple is a Consultant Transplant and Dialysis Access surgeon based at Guys and St Thomas' NHS Foundation Trust and the lead for simulation research. Hannah is the past-Chair of the Ethical, Legal and Psychosocial aspects of Transplantation section (ELPAT) of the European Society of Organ Transplantation and completed the Emerging Leaders Fellowship, awarded by the Royal College of Surgeons of England, in 2023. Resources·       Watch Evelyn Mensah's inaugural address when appointed as the President for the Ophthalmology Section of the Royal Society of Medicine: OPT01 - Equitable, Diverse and Inclusive Ophthalmology through the Eyes of a Geordie Ghanaian - Zoom·       How can I be antiracist·       Cracking the General Surgical Interviews for ST3·       The Kennedy Review·       Medical Workforce Race Equality Standard in England·       GMC data supporting the Medical Workforce Race Equality Standard in England·       NHS Workforce Race Equality StandardNews & Updates from RCS England· RCS England is celebrating the 10-year anniversary of the Emerging Leaders programme. Applications open on 15 May and closes on 1 September 2025.· RCS England: Diversity, Equity & Inclusion / Interested in getting involved or supporting our work? Please contact: diversity@rcseng.ac.uk· The 2025 UK surgical workforce census is now open. It's quick, confidential and crucial. Your voice helps us push for real change where it matters most, from tackling workforce shortages to improving wellbeing and training. Take the census now: https://www.rcseng.ac.uk/standards-and-research/surgical-workforce-census/?utm_source=Digital&utm_medium=TheTheatre&utm_campaign=Census2025Produced by: Andrea PearsonWe would love to hear from you so please do reach out to us on social media, or email us at podcasts@rcseng.ac.uk

In this extraordinary episode, Prue shares her remarkable 11-year journey to motherhood, culminating in becoming the third woman in Australia to give birth following a uterus transplant. Her story is one of incredible perseverance, medical innovation, and the profound desire to become a mother against seemingly impossible odds. If you've been considering joining over 6000 families who have prepared for birth with confidence through The Birth Class now's your chance. You can enjoy 20% off in our Mother’s Day Sale with the code: MUM25Inside The Birth Class you’ll enjoy: 10 comprehensive audio lessons 5 guided meditations for pregnancy and birth 70-page detailed workbook Birth partner cheat sheet Birth positions poster Hospital bag checklist Birth preferences template Lifetime access Save 20% Now [ Code: MUM25 ] Sale ends 15th of May at midnight and applies to all our courses!See omnystudio.com/listener for privacy information.

Unser zweites Thema: Hat es tatsächlich Vorteile für Mutter und Kind, die Plazenta zu essen? Eine Speichelprobe mit einem Wattestäbchen kann der erste Schritt sein, um einem Leukämiepatienten das Leben zu retten. Doch wie funktioniert das Matching für eine Stammzellen- oder Knochenmarkspende – und was passiert bei der Transplantation im Körper? So könnt Ihr Spender werden: https://zkrd.de/registrierung-spende/ Hier der Link zum erwähnten Podcast "Projekt Baby": https://open.spotify.com/show/5d5VYgkx5TeZBoUznLoWYf. "Aha! Zehn Minuten Alltags-Wissen" ist der Wissenschafts-Podcast von WELT. Wir freuen uns über Feedback an wissen@welt.de. Hier der Link zum erwähnten Podcast "Projekt Baby": https://open.spotify.com/show/5d5VYgkx5TeZBoUznLoWYf. Produktion: Serdar Deniz Redaktion/Moderation: Sonja Gillert Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In a special co-branded episode between Oncology On theGo hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Nora M. Gibson, MD, MSCE, and Taha Al-Juhaishi, MD, spoke about real-world applications of betibeglogene autotemcel (beti-cel; Zynteglo) as a treatment for patients with beta (β)-thalassemia.They spoke in the context of a study that Gibson presented at the 2025 Tandem Meetings, which evaluated patients who received commercial beti-cel in a single-center cohort following the agent's FDA approval in August 2022. ¹ ²Nora is a fourth-year fellow in bone marrow transplant andcellular therapy at the Children's Hospital of Philadelphia (CHOP), with a background in clinical research and epidemiology. Al-Juhaishi is the Associate Director of the Hematopoietic Stem Cell Transplantation and Cell TherapyProgram at Oklahoma University Health Stephenson Cancer Center and an assistant professor of Medicine at the University of Oklahoma College of Medicine.Findings from Gibson's study revealed that among 10 patients who underwent stem cell collection at CHOP from 2022 to 2024, beti-cel yielded consistent red blood cell transfusion independence, with investigators notingprolonged platelet engraftment time and high platelet transfusion requirements. Beyond these findings, the conversation focused on how beti-cel compares withother currently available gene therapies for patients with hemoglobin disorders as well as non-curative therapies like allogeneic stem cell transplantation. Gibson and Al-Juhaishi also discussed strategies for mitigating occlusive disease and other potential toxicities associated with beti-cel.“It's a really exciting time to be working in this fieldwhere we finally have really good options for these patients. From our experience and from clinical trials, beti-cel and likely exagamglogene autotemcel [Casgevy]...are very effective, curative therapies for thalassemia in the real-world setting, and we've seen very similar results in sickle celldisease,” said Gibson. “These therapies have been really life-changing for our patients, and they've had a huge reduction in their symptoms and a huge reduction in their burden of health care that's required.”References1.     Gibson NM, Friedman DF, Elgarten CW, et al. Post-approval, real-world experience with betibeglogene autotemcel for transfusion-dependent betathalassemia. Transplantation and Cellular Therapy. 2025;31(2):S254. doi:10.1016/j.jtct.2025.01.386.2.     FDA approves first cell-based gene therapy totreat adult and pediatric patients with beta-thalassemia who require regular blood transfusions. News Release. FDA. August 17, 2022. Accessed April 21, 2025.https://tinyurl.com/3vrkk8kz

In a special co-branded episode between Oncology On the Go hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Nora M. Gibson, MD, MSCE, and Taha Al-Juhaishi, MD, spoke about real-world applications of betibeglogene autotemcel (beti-cel; Zynteglo) as a treatment for patients with beta (β)-thalassemia. They spoke in the context of a study that Gibson presented at the 2025 Tandem Meetings, which evaluated patients who received commercial beti-cel in a single-center cohort following the agent's FDA approval in August 2022. Nora is a fourth-year fellow in bone marrow transplant and cellular therapy at the Children's Hospital of Philadelphia (CHOP), with a background in clinical research and epidemiology. Al-Juhaishi is the Associate Director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of Medicine at the University of Oklahoma College of Medicine. Findings from Gibson's study revealed that among 10 patients who underwent stem cell collection at CHOP from 2022 to 2024, beti-cel yielded consistent red blood cell transfusion independence, with investigators noting prolonged platelet engraftment time and high platelet transfusion requirements. Beyond these findings, the conversation focused on how beti-cel compares with other currently available gene therapies for patients with hemoglobin disorders as well as non-curative therapies like allogeneic stem cell transplantation. Gibson and Al-Juhaishi also discussed strategies for mitigating occlusive disease and other potential toxicities associated with beti-cel. “It's a really exciting time to be working in this field where we finally have really good options for these patients. From our experience and from clinical trials, beti-cel and likely exagamglogene autotemcel [Casgevy]...are very effective, curative therapies for thalassemia in the real-world setting, and we've seen very similar results in sickle cell disease,” said Gibson. “These therapies have been really life-changing for our patients, and they've had a huge reduction in their symptoms and a huge reduction in their burden of health care that's required.” References 1. Gibson NM, Friedman DF, Elgarten CW, et al. Post-approval, real-world experience with betibeglogene autotemcel for transfusion-dependent beta thalassemia. Transplantation and Cellular Therapy. 2025;31(2):S254. doi:10.1016/j.jtct.2025.01.386. 2. FDA approves first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions. News Release. FDA. August 17, 2022. Accessed April 21, 2025. https://tinyurl.com/3vrkk8kz

Host Roz is joined by Timucin Taner, MD, PhD and Dami Ko, PhD to discuss the key articles of the May issue of the American Journal of Transplantation. Dr. Timucin Taner is a professor of surgery at Mayo Clinic, Rochester, MN. Dr. Dami Ko is an assistant professor at the School of Nursing at Northeastern University. [02:51] Development and validation of the Neuro-Score: a specific scale to detect and monitor cognitive impairment in kidney or liver transplant recipients Editorial: Cognitive impairment after liver and kidney transplant: An easy way to check [14:16] Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression [20:46] Donor-specific immune senescence as a candidate biomarker of operational tolerance following liver transplantation in adults: Results of a prospective, multicenter cohort study Editorial: Acquired immune tolerance 2.0 [29:10] Major histocompatibility complex and peptide specificity underpin CD8+ T cell direct alloresponse Editorial: Direct and indirect allorecognition—not so different after all?

CancerNetwork®, in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)®, hosted a Twitter/X Space during the 2025 Tandem Meetings. The live conversation featured Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, and Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center. Together, they shared expert commentary on new data in CAR T-cell therapy and hematopoietic cell transplantation.With insights drawn from posters, oral abstracts, and late-breaking presentations, the session unpacked both clinical takeaways and implications for patient care.Highlights included:LBA1 – Ide-cel + lenalidomide maintenance post-transplant in MM patients“This merges two worlds,” said Banerjee. “Not a tandem in the classic sense, but a transplant followed by CAR T.”[Garfall et al., Abstract LBA-1]Abstract 50 – Real-world CAR T use in early relapsed/refractory LBCLHoltan noted, “In this cohort, no statistical survival difference was seen between second- and third-line therapy, though the curves suggest a trend.”[Rojek et al., Abstract 50]Poster 340 – CAR T targeting CD83 in breast cancerBanerjee speculated on future innovations: “If we could deliver these locally, without systemic effects, that would be a game changer.”[Betts et al., Poster 340]Poster 317 – IEC-colitis in cilta-cel-treated patientsBanerjee reflected, “We assumed steroids would help, like with GVHD. But outcomes didn't align.”[Chang Lim et al., Poster 317]Poster 572 – Driving restrictions post-CAR TBanerjee advocated for updated policy: “Patients often can't regain full independence until driving is restored—this restriction lacks strong evidence.”[Banerjee et al., Poster 572]Presentation 58 – Physical function tests to predict ICANS and mortality“These simple tools helped flag patients unlikely to benefit from CAR T,” said Holtan. “This could refine patient selection.”[Herr et al., Presentation 58]Poster 618 – HCT outcomes for MDS patients by age groupHoltan expressed optimism: “We need conditioning regimens that are effective yet gentler—especially for older patients.”[Duarte et al., Poster 618]Presentation 39 – Immune suppression trends post-HCT (18,000+ patients)Looking ahead, Holtan predicted a shift in GVHD care: “In 10 years, steroids may no longer be our go-to.”[Pidala et al., Presentation 39]Poster 516 – Patient experiences with chronic GVHD via social media listeningHoltan emphasized the human element: “We must prioritize mental health, community support, and advocacy alongside clinical treatment.”[Cowden et al., Poster 516]The discussion emphasized not only the clinical relevance of each study but also broader themes—improving quality of life, adjusting standards of care based on real-world findings, and advancing innovation through thoughtful, patient-centered research.References:Garfall AL, et al. Abstract LBA-1. Tandem 2025.Rojek AE, et al. Abstract 50. Tandem 2025.Betts BC, et al. Poster 340. Tandem 2025.Chang Lim KJ, et al. Poster 317. Tandem 2025.Banerjee R, et al. Poster 572. Tandem 2025.Herr M, et al. Presentation 58. Tandem 2025.Duarte FB, et al. Poster 618. Tandem 2025.Pidala J, et al. Presentation 39. Tandem 2025.Cowden M, et al. Poster 516. Tandem 2025.

Dr. Justin Abbatemarco provides an update on autologous hematopoietic stem cell transplantation in multiple sclerosis. Show reference: https://www.nature.com/articles/s41582-024-01050-x

Host: Darryl S. Chutka, M.D. Guest: John Haney, M.D., M.P.H. Lung transplantation remains a very viable option for patients with end-stage pulmonary disease who no longer respond to medical management. Over 5,000 lung transplants are performed annually around the world. However, its estimated that over 10 times this number are candidates and awaiting a transplant. A shortage of organs remains the major limiting factor. What are the common indications and who's a candidate for a lung transplant? How are patients prioritized and chosen? What advances have been made in the field and what challenges remain? Finally, what role does the primary care clinician play in lung transplantation? I'll be discussing these questions and more with my guest, Jack Haney, M.D., M.P.H., chair of cardiothoracic surgery at the Jacksonville campus of the Mayo Clinic. The topic for this podcast is “Lung Transplantation”. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Host Roz is joined by Rene Bermea, MD and Gonzalo Sapisochin, MD, PhD to discuss the key articles of the April issue of the American Journal of Transplantation. Dr. Rene Bermea is an instructor at Harvard Medical School, and a transplant pulmonologist and intensivist. Dr. Gonzalo Sapisochin is an associate professor of surgery, abdominal transplant and surgical oncology at the University of Toronto, Canada. [04:31] Generalizability of kidney transplant data in electronic health records — The Epic Cosmos database vs the Scientific Registry of Transplant Recipients Editorial: Finding actionable information in the universe of data [14:17] High-dimensional profiling of immune responses to kidney transplant reveals heterogeneous T helper 1 and B cell effectors associated with rejection Editorial: Multimodal profiling of transplant rejection: Discerning the forest from the trees [23:02] The ability of an electronic nose to distinguish between complications in lung transplant recipients [34:58] The Rochester Protocol for living donor liver transplantation of unresectable colorectal liver metastasis: A 5-year report on selection, approval, and outcomes

April 19 is World Liver Day, a day to raise awareness about the health of our often-overlooked yet vital liver. Liver diseases are a leading cause of mortality in the Philippines, accounting for 27.3 per 1,000 deaths, according to a 2023 study published in the Annals of Hepatology.Experts also warn that 10-20% of Filipinos may have non-alcoholic fatty liver disease, which can lead to serious complications if left untreated.To share tips on how to take care of our liver, we spoke with Dr. Maria Vanessa H. De Villa, the first surgeon in the country to perform a pediatric liver transplant and the director of The Medical City's Center for Liver Disease Management and Transplantation.Interview by Edg Adrian EvaAudio editing by Jayson Mariñas

Host: Darryl S. Chutka, M.D. Guest: Rohan M. Goswami, M.D. The benefits of artificial intelligence or AI are just beginning to be recognized. AI has the potential to improve productivity and efficiency in the workplace, reduce errors and help sort out complex issues. The field of healthcare is finding roles for AI by improving the management of patient data, enhancing clinical decision making and assisting in medical imaging analysis. The integration of AI in transplantation medicine is evolving and has the potential to revolutionize the field. Can AI assist in organ matching and allocation? Can it predict graft survival and organ rejection?  What ethical concerns does AI bring to the specialty?  I'll be discussing these issues in this podcast as we tackle the topic of “AI in Transplantation Medicine”. My guest for this podcast is Rohan M. Goswami, M.D., a cardiologist and specialist in Transplant Medicine from the Mayo Clinic. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Our next AAOS 2025 Annual Meeting poster is titled Mid-term Follow-up of Patellofemoral Osteochondral Allograft Transplantation. This study was performed by Dr. Bill Bugbee and his team at the Scripps Clinic. Dr. Bugbee was a guest on our show back in November 2023.  That is episode 59 and 60, if you want to go check it out.  In that episode, we discussed osteochondral allograft transplantation for various cartilage defects of the knee, including medial and lateral tibiofemoral, which are the more common locations for OCA transplantation.  This study focuses specifically on outcomes of OCA transplantation for patellofemoral cartilage defects.This study identified 127 patients undergoing OCA transplantation in the patellofemoral compartment – 51 to the patella, 47 to the trochlea and 29 bipolar patella and trochlea.  The most common indication was a degenerative cartilage lesion at 47%, followed by a traumatic cartilage injury at 25% and osteochondritis dissecans at 15%.  All patients had a minimum follow-up of 2 years.  OCA failure was defined as any reoperation that involved removal of the allograft.  Patient reported outcomes were also assessed pre-op and post-op, including the IKDC score and KOOS score.So, what did this study find?  First, reoperations occurred in 39% of the knees.  Rate of reoperation was not statistically significant between patella, trochlea and bipolar grafts.  Second, OCA failures occurred in 16% of the knees at a median 4.4 years following the index surgery, and the most common revision procedure was arthroplasty.  Although it did not reach statistical significance, trochlear grafts had a lower failure rate of 9% compared to patellar grafts at 20% and bipolar grafts at 21%.Overall, graft survivorship at 5 and 10 years was 91% and 82%, respectively.  Patients with patellar, trochlear and bipolar grafts all had significant improvement in IKDC scores and KOOS scores from preop to the latest follow-up and no statistically significant differences were observed between the groups.  Overall, 77% of patients reported being satisfied with the results of the OCA transplantation with no statistically significant differences in satisfaction between the groups.Also check out:Episode 91: Dr. Tom DeBerardino 0n Advances in Patellofemoral Cartilage Restoration

Host: Darryl S. Chutka, M.D. Guests: Nitin N. Katariya, M.D., and Lavanya Kodali, M.B.B.S., M.D. At this time, about 11% of the population in the U.S. has diabetes.  This represents nearly 40 million people. And this number is increasing, not only in the U.S. but around the world. Although we have more medical options now than ever before for managing diabetes, the treatment is less than optimal. Another option is a pancreas transplant. What's the status of pancreatic transplantation? Who's a candidate for the procedure? How effective is it and what does the future hold for the procedure?  The topic for this podcast is “Pancreas Transplantation” and I'll be discussing these questions with Nitin N. Katariya, M.D., a transplant surgeon and Lavanya Kodali, M.B.B.S., M.D., a nephrologist and specialist in renal transplant, both from the Arizona campus of the Mayo Clinic. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on Twitter @MayoTransplant To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Host: Darryl S. Chutka, M.D. Guest: C. Burcin Taner, M.D. Recently, the criteria for organ donors have expanded in order to address the increasing difference between the number of available organs and the demand for transplants. Advancements in medical technology, a better understanding of transplant immunology, and the improvement of transplant surgery techniques have allowed for the inclusion of a greater pool of donors with various health conditions, which excluded them as donors in the past. Understanding the delicate balance between expanding the criteria for transplantation and maintaining a high quality of life for the recipients has been important in advancing the field of organ transplantation. The topic for this podcast is “Expanded Donor Criteria for Organ Transplantation” and my guest is C. Burcin Taner, M.D., Professor of Surgery and Chair of the Department of Transplantation at the Florida campus of the Mayo Clinic. Learn more about our Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on Twitter @MayoTransplant To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Marine Le Pen ist wegen Veruntreuung von EU-Geldern verurteilt worden. Nun darf sie unter anderem fünf Jahre lang nicht in ein politisches Amt gewählt werden - ein Erdbeben in der politischen Landschaft Frankreichs. Eine Expertin ordnet ein. Weitere Themen: · Die Verkäufe von Tesla sind eingebrochen. Wir haben die neuesten Zahlen aus der Schweiz · Ein umstrittenes Kanalprojekt soll Pakistan fruchtbar machen. Kritiker:innen fürchten eine Wasserknappheit. · Erste erfolgreiche Transplantation einer Schweineleber: In China ist eine Schweineleber einem hirntoten Menschen eingesetzt worden. Ein medizinischer Meilenstein, sagen Fachleute.

This week we review a recent PHTS study on long-term outcomes following heart transplantation. Why do patients develop coronary vasculopathy and how commonly is it seen at long term follow-up? What factors are associated with better or worse long term outcomes? How do 'adverse childhood experiences' result in worse outcomes for patients? Why do young transplant patients have better long-term outcomes and can this be leveraged to improve older patient outcomes? We speak with the first author of this week's work, Assistant Professor of Pediatrics at Ohio State and also from Nationwide Children's Hospital, Dr. Emily Hayes. DOI: 10.1111/petr.70042

In this week's episode, we'll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles:Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationHow I diagnose and treat acute infection–associated purpura fulminansSickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Autologous haematopoietic stem cell transplantation (AHSCT) has gained considerable attention in recent years as a treatment option for multiple sclerosis (MS). As long-term clinical trial data on AHSCT continues to grow, there is increasing debate about where it fits in the current MS therapeutic landscape. Dr. Joachim Burman, Neurologist and Associate Professor at Uppsala University in Sweden, and Dr. Jennifer Massey, Neurologist at St. Vincent's Hospital and a Senior Lecturer at the University of New South Wales in Australia, discuss the latest research and insights on this hot topic with host Brett Drummond of MStranslate.

This week on Health Matters, Courtney Allison is joined by infectious disease expert from NewYork-Presbyterian and Columbia, Dr. Marcus Pereira, to learn what we need to know about bird flu.Dr. Pereira explains that while the cases of bird flu in humans have been mostly mild, there is still a risk that the virus could mutate and spread more easily from human-to-human. He talks about ways to protect ourselves from bird flu, and explains whether it's safe to eat eggs, meat and other dairy products.___Dr. Marcus Pereira is an Associate Professor of Medicine at CUMC and the Director of Clinical Services in the Division of Infectious Diseases. In addition, he is the Medical Director of the Transplant Infectious Diseases Program, where he oversees the development of infection prophylaxis and treatment protocols for immunocompromised patients. His areas of interest include the management of multi-drug resistant bacterial and fungal infections, as well as drug resistant CMV infections and more recently the impact of COVID-19 in transplant recipients. He has also collaborated in important multi-center studies as well as the 2025 International CMV Guidelines, sponsored by the Transplantation Society. Dr. Pereira is an active member in national societies such as the American Society of Transplantation and Infectious Disease Society of America, and is an Associate Editor for the American Journal of Transplantation.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org

Jonathan Fairbairn (standing in for Relebogile Mabotja) speaks to Dr Kashmal Kalan a Medical Director for AlviArmani South Africa about hair loss and hair transplantation. See omnystudio.com/listener for privacy information.

Host: Michelle Kittleson, MD, PhD Transthyretin cardiac amyloidosis (ATTR-CM) is an underrecognized disorder, leading to a variety of unmet needs for patients. Dr. Michelle Kittleson, Director of Postgraduate Education in Heart Failure and Transplantation and Professor of Medicine at the Cedars-Smidt Heart Institute, explores these challenges and discusses how early recognition, genetic screening, and emerging therapies can help improve patient outcomes.

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning examines surgical staplers. He explores the history of surgical staplers, the evolution of surgical staplers, and discusses the company that created the first automated minimally invasive surgical stapler—United States Surgical Corporation (USSC). He also discusses details about the AutoSuture Premium Poly stapler and why it is still being created. Joel also shares details about when he visited a production line that is responsible for creating surgical staplers. He discusses his experience and his highlights from this event, which includes meeting Dr. Rene Petersen and Dr. Laurens Ceulemans.  Joel also reviews recent JANS articles on heart transplantation and donation after circulatory death in children, priorities for medical device regulatory approval, transplantation of a genetically modified porcine heart into a live human, and mechanisms of repair failure after mitral valve repair using chordal replacement.   In addition, Joel explores treating intractable hiccups by clipping the phrenic nerve using VATS, robotic totally endoscopic CryoMaze ablation under ventricular fibrillatory arrest, and a new podcast episode from Dr. Alice Copperwheat, “The Atrium: Internal Mammary Artery Harvesting,” with expert guest Dr. David Taggart. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Heart Transplantation and Donation After Circulatory Death in Children. A Review of the Technological, Logistical and Ethical Framework  2.) Priorities for Medical Device Regulatory Approval: A Report From the European Society of Cardiology Cardiovascular Round Table  3.) Transplantation of a Genetically Modified Porcine Heart Into a Live Human  4.) Mechanisms of Repair Failure After Mitral Valve Repair Using Chordal Replacement  CTSNET Content Mentioned  1.) Treating Intractable Hiccups by Clipping the Phrenic Nerve Using VATS  2.) The Atrium: Internal Mammary Artery Harvesting  3.) Robotic Totally Endoscopic Cryo-Maze Ablation Under Ventricular Fibrillatory Arrest  Other Items Mentioned  1.) Career Center   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Jan Van Slambrouck, MD, to discuss the paper, “The effect of rewarming ischemia on tissue transcriptome and metabolome signatures: A clinical observational study in lung transplantation.”   Dr. Van Slambrouck is a general surgeon who's just finished his PhD training at the KU Leuven lab of respiratory disease and thoracic surgery in Belgium.   The episode explores:  How rewarming ischemia time (RIT) affects donor lungs, especially on the molecular level The pace of rewarming and how prior literature prepared the team to track and evaluate it Clinical strategies to reduce RIT and directly address molecular changes   For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Those involved in the pulmonary vascular disease space should tune in again later this month for a study on the safety and efficacy of riociguat in patients with PAH.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.  The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee's and Holtan's respective areas of expertise. The following trials were discussed: LBA1 - Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial1 “This [study] is nice because it merges 2 worlds. It's like a tandem—but not really a tandem—because you're not doing 2 transplants back-to-back. You're doing a transplant followed by CAR T-cell therapy,” said Banerjee. Abstract 50 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium2 “In a relatively small cohort, [investigators] found no difference in 9-month survival whether someone got their [CAR T cells] in second-line therapy vs third-line therapy from a statistical perspective. If you look at the curves, it looks like there is a potential benefit to second-line therapy, but there was not enough statistical power to determine a difference,” said Holtan. Poster 340 - CD83 Expression By Human Breast Cancer Mediates Effective Killing By CAR T3 “If there's a way to do [the therapy] armored and have a paracrine delivered in real time—and not given to the whole body—[so] the patient [would] have all the adverse effects and cytokine release syndrome release on their own…that would be awesome,” stated Banerjee.  Poster 317 - Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)4 “From the best that we can tell, ironically, corticosteroids aren't the fix that we want them to be [for immune effector cell-associated colitis]…We were like ‘Diarrhea, whatever. Let's give some steroids and treat it like gut graft-versus-host-disease,' but these patients [didn't] respond as well [to that],” said Banerjee. Poster 572 - Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium5 “Patients and their caregivers [who have] put their life aside for 4 weeks just to get through CAR T-cell therapy and the Risk Evaluation and Mitigation Strategies requirements are now being told ‘You're free to go, but you can't drive for 4 weeks, which means you can't get your own groceries or…go to doctor's appointments by yourself.' Basically, we argue…that this [requirement] is not evidence-based,” stated Banerjee.  Presentation 58 - Physical Function Measures Identify Non-Hodgkin Lymphoma Patients at High Risk of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and 1-Year Mortality after Chimeric Antigen Receptor T (CAR-T) Cell Therapy6 “This [presentation] highlights that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from CAR T-cell therapy, and these tests are so simple to do. It's going to be interesting to see if others can reproduce this,” said Holtan. Poster 618 - Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry7 “My personal hope for this space is that our field can come up with more novel conditioning regimens such that we can ablate the marrow without causing those gastrointestinal toxicities or other organ toxicities [while] doing that so effectively that we don't even need maintenance therapies for a lot of conditions,” stated Holtan. Presentation 39 - Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects8 “I'm going to make a provocative prediction for the next paper [approximately 10 years from now]. I predict that steroids won't be the first-line therapy for acute or chronic graft-versus-host-disease,” Holtan said. Poster 516 - Patient Experiences with Chronic Graft-Versus-Host Disease and Its Treatment in the United States: A Retrospective Social Media Listening Study9 “We can still work together to make life as good as we possibly can [for patients], to improve physical function, to take away some of this mental distress, and then work together for advocacy too. [We can] help with peer support, help with resources, and help relieve some of that misunderstanding in the community,” stated Holtan. References 1.        Garfall AL, Pasquini MC, Bai L, et al. Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract LBA-1. 2.        Rojek AE, Ahmed N, Gomez-Llobell M, et al. CAR T cell therapy in early relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 50. 3.        Betts BC, Davilla ML, Linden AM, et al. CD83 expression by human breast cancer mediates effective killing by CAR T. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 340. 4.        Chang Lim KJ, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 317. 5.        Banerjee R, Richards A, Khouri J, et al. Post-CAR-T driving restrictions appear unnecessary after week 4: data from the US multiple myeloma immunotherapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 572. 6.        Herr M, McCarthy P, Jacobsen H, et al. Physical function measures identify non-Hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 58. 7.        Duarte FB, Garcia YDO, Funke VAM, et al. Comparison of outcomes after hematopoietic STEM cell transplantation (HCT) for myelodysplastic syndrome (MDS) patients older or younger THAN 65 YEARS Old. A retrospective analysis of the Latin America registry. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 618. 8.        Pidala J, DeFlilipp Z, DeVos J, et al. Determinants of immune suppression discontinuation in the modern era: a CIBMTR analysis of 18,642 subjects. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 39. 9.        Cowden M, Derrien-Connors C, Holtan S, et al. Patient experiences with chronic graft-versus-host disease and its treatment in the United States: A retrospective social media listening study. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 516.

Host Roz is joined by Ross Doyle, PhD to discuss the key articles of the March issue of American Journal of Transplantation. Dr. Ross Doyle is a consultant nephrologist at Mater Hospital in Dublin, Ireland. (Mentioned) A blood-based PT-LIFE (Pediatric Liver Transplantation-LIver Fibrosis Evaluation) biomarker panel for noninvasive evaluation of pediatric liver fibrosis after liver transplantation: A prospective derivation and validation study Editorial: Are we closer to abandoning protocol graft biopsies after pediatric liver transplantation? (Mentioned) Deceased donor urinary Dickkopf-3 associates with future allograft function following kidney transplantation [04:08] Cure models, survival probabilities, and solid organ transplantation for patients with colorectal cancer Editorial: When is it safe to transplant after cancer–adding data to the decision [11:05] Navigating challenges in recipient selection for end-chain kidneys [18:00] Severe ischemia-reperfusion injury induces epigenetic inactivation of LHX1 in kidney progenitor cells after kidney transplantation [28:31] The differential impact of early graft dysfunction in kidney donation after brain death and after circulatory death: Insights from the Dutch National Transplant Registry

The process of liver transplantation involves many complexities, and each patient's path to transplant is unique. To offer insider perspectives on this process, Dr. Zachary Berman sits down with transplant and hepatobiliary surgeon Dr. John Seal, as well as transplant hepatologists Dr. Heather Patton and Dr. Steve Young. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125740 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The panel begins by discussing the multidisciplinary pre-transplant evaluation process, which assesses factors such as liver function, comorbidities, surgical risk, and the availability of psychosocial support. Once a patient is listed for transplant, they enter a system that prioritizes those with the highest Model for End-Stage Liver Disease (MELD) score. During the waiting period, several comorbidities should be carefully monitored. Dr. Seal explores the impact of portal vein hypertension and portal vein thrombosis, explaining how these conditions may necessitate intraoperative thrombectomy or bypass. Dr. Patton and Dr. Young focus on considerations for using anticoagulation in patients with a high baseline bleeding risk and selecting the appropriate anticoagulant for patients listed for transplant. For patients with hepatocellular carcinoma (HCC), eligibility for MELD exception points may depend on factors such as time spent on the waiting list, adherence to the Milan criteria, and the presence of extrahepatic complications of liver disease. The panel also discusses bridging therapies to transplant, including Y90 and TACE. In the peri-transplant phase, they highlight innovations such as living donor transplants, liver perfusion pumps, and the use of hepatitis C- and HIV-positive organs. Finally, the discussion turns to post-transplant considerations, including surgical complications, organ rejection, immunosuppression, predictors of HCC recurrence, and long-term surveillance. --- TIMESTAMPS 00:00 - Introduction 01:16 - Current Landscape of Liver Transplantation 03:22 - Transplant Evaluation Process 09:48 - Timeline from Listing to Transplantion 11:16 - Treating Portal Vein Thrombosis and Hypertension 18:44 - MELD Exception Points 22:05 - Bridging Therapies 25:34 - Peri-Transplant Considerations 30:53 - Post-Transplant Period 37:39 - Repeat Transplantation --- RESOURCES Model for end-stage liver disease (MELD) and allocation of donor livers (Wiesner et al, 2003): https://www.gastrojournal.org/article/S0016-5085%2803%2950022-1/fulltext Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis- Milan Criteria (Mazzaferro et al, 1996): https://pubmed.ncbi.nlm.nih.gov/8594428/ Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database (Mehta et al, 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6445634/ CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Join Dr. Steven Devine, Chief Medical Officer at the National Marrow Donor Program and Executive Lead at the CIBMTR®, as he shares groundbreaking advancements in donor availability, transplant processes, and patient care. Discover how new strategies are expanding access to life-saving treatments, particularly for diverse populations, and learn about the collaborative efforts driving these transformative innovations.

Join Dr. Steven Devine, Chief Medical Officer at NMDP, formerly known as the National Marrow Donor Program or Be the Match, and Executive Lead at the CIBMTR®, as he shares groundbreaking advancements in donor availability, transplant processes, and patient care. Discover how new strategies are expanding access to life-saving treatments, particularly for diverse populations, and learn about the collaborative efforts driving these transformative innovations.

Heart Lung Transplantation   Guest: Richard C. Daly, M.D. Guest: Philip J. Spencer, M.D. Host: Kyle Klarich, M.D.   Heart lung transplantation is the transplant of the combined heart-lung organ bloc from a donor into a recipient who has end-stage disease of both the heart and the lungs.  This is often necessary because the disease in 1 of the organs (the heart or the lungs) caused the disease in the other organ system.  For example, pulmonary hypertension might cause gradual but irreversible right ventricular failure in the heart.  The prognosis after heart-lung transplantation is similar to patients who receive isolated lung transplantation.   Topics Discussed: Heart-lung transplantation and why it is unique.? Types of diseases that would require heart-lung transplantation. Prognosis after heart-lung transplantation compared to heart transplant and lung transplant survival. Immunologic advantages to block heart-lung transplantation.   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

About our guest … Mason Van Houweling Mason Van Houweling serves as the Chief Executive Officer of the University Medical Center of Southern Nevada (UMC), providing leadership to a diverse team of nearly 5,000 employees who dedicate their careers to delivering Nevada's highest level of care. While guiding Nevada's most respected academic medical center and its many off-site clinic locations, Mason's strategic vision supports the organization's ability to save and improve the lives of community members. UMC remains dedicated to offering exclusive and highly specialized services, including Nevada's Level I Trauma Center, only Verified Burn Center, and only Center for Transplantation. As a result of his commitment to innovation, UMCnow serves as Nevada's most sophisticated healthcare system, offering the latest breakthroughs in clinical technology. Mason brings 30 years of healthcare experience to UMC, from small community hospitals to those with more than 1,000 beds. He has a proven track record of balancing a hospital's financial performance while providing uncompromised patient care. Mason's hospital administration career began at Orlando Regional Medical Center and continued progressing with Tenet Healthcare, CarolinasHealthcare System, and Universal Healthcare. Before joining UMC as Chief Executive Officer, Mason was a Senior Leader at Spring Valley and Valley Hospitals in Las Vegas, Nevada.

Hosts Roz and Josh are joined by Dr. Adam Stewart to discuss the key articles of the February issue of the American Journal of Transplantation.   [00:02:38] A competing risks model to estimate the risk of graft failure and patient death after kidney transplantation using continuous donor-recipient age combinations [00:09:00] Donor-derived bartonellosis in solid organ transplant recipients from unhoused donors in Alberta [00:16:54] Contemporary prevalence and practice patterns of out-of-sequence kidney allocation Editorial: Out-of-sequence allocation: a necessary innovation or a new inequity in transplantation? Editorial: Ethical implications of prioritizing utility at all costs: The rise of out-of-sequence transplants [00:28:18] Association of nonstandardized model for end-stage liver disease score exceptions with waitlist mortality in adult liver transplant candidates

Drs. Solomon and Swigris review how they discuss lung transplantation with patients with ILDs, as well their philosophies of addressing end-of-life issues and the use of opioids in managing symptoms in these patients.

On the Naked Scientists News show: a new UK trial seeks to infect healthy people with malaria in a bid to get to grips with the dormant stage of the infection. Then, we hear how T cells could be the key to ensuring more organ transplant successes, and should we all be taking fewer flights? Also, some curious observations regarding chimpanzees and their communal toilet routines... Like this podcast? Please help us by supporting the Naked Scientists

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Lori Muffly, Associate Professor in the Division of Blood and Marrow Transplantation-Cellular Therapies at Stanford University, to discuss groundbreaking advancements in graft selection and manipulation in hematopoietic cell transplantation. They explore the evolution of graft engineering strategies aimed at improving patient outcomes, with a focus on Orca-T, an innovative cell therapy designed to reduce graft-versus-host disease while maintaining graft-versus-leukemia effects. Dr. Muffly provides insights into the clinical development of this promising therapy, its impact on patient recovery, and the future of transplantation. Tune in to learn about the latest research and what it means for the future of cellular therapy.

Hosts Roz and Josh are joined by Sergio Acuna, MD to discuss the key articles of the January issue of American Journal of Transplantation. Dr. Sergio Acuna is a clinical instructor in abdominal transplant surgery at the University of Alabama at Birmingham   [03:21] The dangerous precedent of censoring scientific dissemination [08:45] Long-term ex situ normothermic machine perfusion allows regeneration of human livers with severe bile duct injury Editorial: Time will tell: Employing long-term normothermic machine perfusion to gain new insight into bile duct regeneration [14:00] Probable antibody-mediated rejection in kidney transplantation is a rare and challenging phenotype to define: Findings from a single-center study [19:54] The relationship of microvascular inflammation with antibody-mediated rejection in kidney transplantation Editorial: Exploring microvascular inflammation and the spectrum of antibody-mediated rejection [25:56] Long-term persistence of seroprotection against measles following measles-mumps-rubella vaccination administered before and after pediatric liver transplantation [31:26] Detection of viral RNA and DNA and immune response following administration of live attenuated measles and varicella vaccines in children with chronic liver disease

Drs. Anne-Grete Märtson, Megan Wimmer, and Evan Clemens join Dr. Erin McCreary to tackle the one of the hottest debates among providers taking care of immunocompromised patients, valganciclovir dosing! Learn all about the history of valganciclovir dosing, what is valganciclovir's PK/PD target, and even valganciclovir therapeutic drug monitoring. References: Märtson AG, Edwina AE, Kim HY, Knoester M, Touw DJ, Sturkenboom MGG, Alffenaar JC. Therapeutic Drug Monitoring of Ganciclovir: Where Are We? Ther Drug Monit. 2022 Feb 1;44(1):138-147. doi: 10.1097/FTD.0000000000000925. PMID: 34610621; PMCID: PMC8746890. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP; Valganciclovir Solid Organ Transplant Study Group. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005 Jun 15;79(11):1477-83. doi: 10.1097/01.tp.0000164512.99703.ad. PMID: 15940035. This podcast is powered by Pinecast.